New Success Data on LucentisNewly released results from the Lucentis studies show just how successful the macular degeneration drug is.The latest, two-year information from the Lucentis studies revealed positive new findings about the success of the drug. The study demonstrated that the patients who's visual acuity improved from Lucentis therapy, maintained their improved vision at year two.  Since age-related macular degeneration is an ongoing, progressive eye disease, the news that vision improvements from Lucentis last at least two years is exciting.
The study also showed that 90% of patients treated with 0.3mg and 0.5mg Lucentis either maintained or improved vision and up to 41% of Lucentis patients had improved vision. Related information: New Lucentis v. Stroke Information Interim Lucentis study data showed that, at six months into the study, Lucentis use in stroke patients may lead to an increased risk of stroke.
However, once the final study was complete, results showed that there was no associated risk of stroke in patients getting Lucentis treatment.ref: Review of Ophthalmology | 
